CN113122472B - 一株能够保护肠道通透性的普通拟杆菌及其应用 - Google Patents
一株能够保护肠道通透性的普通拟杆菌及其应用 Download PDFInfo
- Publication number
- CN113122472B CN113122472B CN202110377659.9A CN202110377659A CN113122472B CN 113122472 B CN113122472 B CN 113122472B CN 202110377659 A CN202110377659 A CN 202110377659A CN 113122472 B CN113122472 B CN 113122472B
- Authority
- CN
- China
- Prior art keywords
- bacteroides vulgatus
- ccfm1152
- bacteroides
- intestinal
- intestinal permeability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000606215 Bacteroides vulgatus Species 0.000 title claims abstract description 74
- 230000003870 intestinal permeability Effects 0.000 title abstract description 21
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000009629 microbiological culture Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 abstract description 23
- 238000004321 preservation Methods 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 7
- 244000005700 microbiome Species 0.000 abstract description 7
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 238000004904 shortening Methods 0.000 abstract description 3
- 230000004580 weight loss Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 28
- 239000001963 growth medium Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 229920003045 dextran sodium sulfate Polymers 0.000 description 20
- 241000606125 Bacteroides Species 0.000 description 17
- 244000068988 Glycine max Species 0.000 description 17
- 235000010469 Glycine max Nutrition 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 238000012258 culturing Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 14
- 239000008267 milk Substances 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000010802 sludge Substances 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 8
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 8
- 229940025294 hemin Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000015140 cultured milk Nutrition 0.000 description 6
- 239000002068 microbial inoculum Substances 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 229940073490 sodium glutamate Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 235000015192 vegetable juice Nutrition 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 244000174681 Michelia champaca Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 241001052560 Thallis Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000020426 cherry syrup Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 210000005206 intestinal lamina propria Anatomy 0.000 description 1
- 230000004675 intestinal mucosal permeability Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株能够保护肠道通透性的普通拟杆菌及其应用,属于微生物技术领域。本发明提供的普通拟杆菌CCFM1152已于2020年11月9日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No.61279。本发明提供的普通拟杆菌CCFM1152可以有效保护由于DSS诱导的体重下降、结肠长度变短、降低肠道通透性,修复结肠黏膜损伤。因此,普通拟杆菌CCFM1152在制备保护肠道通透性的食品和微生态制剂方向具有广泛的应用前景。
Description
技术领域
本发明涉及一株能够保护肠道通透性的普通拟杆菌及其应用,属于微生物技术领域。
背景技术
溃疡性结肠炎(UC)是一种典型的慢性复发性特发性肠道炎症,可引发结肠黏膜炎症、直肠出血和腹泻等。溃疡性结肠炎往往伴随着肠黏膜炎症和肠上皮屏障功能紊乱,其主要病理表现是肠黏膜通透性增加。研究发现,与正常组织相比,溃疡性结肠炎的肠组织中紧密连接结构和功能发生改变,肠黏膜通透性增加。而肠黏膜通透性会导致细菌、脂质多糖和内毒素等大分子物质透过损伤的肠黏膜进入组织而诱导或加剧炎症等。因此,保护肠道通透性进而改善肠道屏障恢复肠粘膜损伤是预防或者缓解结肠炎的有效途径。过往的研究已经表明益生菌在保护肠道健康,降低肠道通透性方面的巨大潜力。例如专利CN107412272A提供了一株植物乳杆菌Sc52,可以缓解由LPS刺激引起的肠道通透性增加。专利CN105795111A提供了一种包含唾液乳杆菌和鼠李糖乳杆菌微生态饲料添加剂,也能降低肠道的通透性。
拟杆菌是下一代益生菌的候选细菌之一,由于其对人类健康的潜在益处,已受到一定的关注。已有研究表明,某些拟杆菌可以调节机体代谢,抑制病原菌定居,减轻肠道炎症等。其中,普通拟杆菌是一种与肠道炎症密切相关的拟杆菌种。例如,一份报告显示,克罗恩病或溃疡性结肠炎患者肠道菌群中普通拟杆菌的丰度高于健康的人类肠道菌群。Frick等人的另一项研究表明,普通拟杆菌mpk通过抑制白介素-8(IL-8)的产生,可以预防小鼠DSS和小肠结肠炎耶尔森菌诱导的急性结肠炎。此外,Steimle等人的研究强调普通拟杆菌缓解肠道炎症的潜在作用。他们发现,普通拟杆菌表面的脂多糖可以通过肠固有层CD11c+细胞的MD-2/TLR4受体复合物轴诱导一种特殊的内毒素耐受,从而帮助重建肠道免疫稳态。鉴于普通拟杆菌在溃疡性结肠炎干预特性上的独特优势,筛选更多具有有益潜力的益生型普通拟杆菌值得研究。尽管一些专利(如CN111269852A)已经表明了普通拟杆菌具有改善调节肠道炎症的显著功效。但是到目前为止,还没有普通拟杆菌可以保护肠道通透性的专利报道。
发明内容
[技术问题]
目前关于普通拟杆菌对肠道中保护肠道通透性的研究及应用仍处于空白状态,需筛选一株能够保护肠道通透性的普通拟杆菌(Bacteroides vulgatus)。
[技术方案]
为了解决上述问题,本发明提供了一种普通拟杆菌(Bacteroides vulgatus)CCFM1152,该菌株已于2020年11月9日保藏于广东省微生物菌种保藏中心,保藏地址为广州市先烈中路100号大院59号楼5楼广东省微生物研究所,保藏编号为GDMCC No.61279。
本发明还提供了含有上述普通拟杆菌CCFM1152的微生物制剂。
在本发明的一种实施方式中,所述微生物制剂中,所述普通拟杆菌CCFM1152的活菌数不低于1×106CFU/mL或1×106CFU/g。
本发明还提供了一种保护小鼠肠道通透性的产品,所述产品中含有上述普通拟杆菌CCFM1152或上述微生物制剂。
在本发明的一种实施方式中,所述产品中,上述普通拟杆菌CCFM1152的活菌数不低于1×106CFU/mL或1×106CFU/g。
在本发明的一种实施方式中,所述产品包括药物。
在本发明的一种实施方式中,所述药品含有上述普通拟杆菌CCFM1152、药物载体和/或药用辅料。
本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
本发明的一种实施方式中,所述药用辅料包含填充剂、粘合剂、润湿剂、崩解剂、润滑剂和/或矫味剂。
在本发明的一种实施方式中,所述填充剂为淀粉、蔗糖、乳糖、硫酸钙和/或微晶纤维素。
在本发明的一种实施方式中,所述粘合剂为纤维素衍生物、藻酸盐、明胶和/或聚乙烯吡咯烷酮。
在本发明的一种实施方式中,所述润湿剂为水、乙醇、淀粉和/或糖浆。
在本发明的一种实施方式中,所述崩解剂为羧甲基淀粉钠、羧丙纤维素、交联羧甲基纤维素、琼脂、碳酸钙和/或碳酸氢钠。
在本发明的一种实施方式中,所述润滑剂为滑石粉、硬脂酸钙、硬脂酸镁、微粉硅胶和/或聚乙二醇。
在本发明的一种实施方式中,所述矫味剂为单糖浆、蔗糖、卵磷脂、橙皮糖浆、樱桃糖浆、柠檬、茴香、薄荷油、海藻酸钠、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素钠、柠檬酸、酒石酸和/或碳酸氢钠。
本发明的一种实施方式中,所述药品的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
本发明还提供了上述普通拟杆菌CCFM1152或上述微生物制剂在制备改善肠道健康的药物中的应用。
本发明的有益效果:
本发明的普通拟杆菌CCFM1152可显著将因葡聚糖硫酸钠(DSS)感染而造成的小鼠体重下降、结肠长度变短、结肠组织病理损伤以及肠道通透性增加恢复至接近正常小鼠水平。因此,本发明所述具有保护肠道通透性的普通拟杆菌株在食品和微生态制剂方向具有广泛的应用前景。
生物材料保藏
本发明提供了一种普通拟杆菌(Bacteroides vulgatus)CCFM1152,该菌株已于2020年11月9日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No.61279,保藏地址为广州市先烈中路100号大院59号楼5楼广东省微生物研究所。
附图说明
图1:普通拟杆菌对结肠炎小鼠体重的影响(与DSS组对比,***表示P<0.001,**表示P<0.01,*表示P<0.05)。
图2:普通拟杆菌对结肠炎小鼠结肠长度的影响(与DSS组对比,***表示P<0.001,**表示P<0.01,*表示P<0.05)。
图3:普通拟杆菌对肠道通透性的影响(与DSS组对比,***表示P<0.001,**表示P<0.01,*表示P<0.05)。
图4:小鼠结肠组织形态学观察(与DSS组对比,***表示P<0.001,**表示P<0.01,*表示P<0.05)。
具体实施方式
为了使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明的优选实施例进行详细的描述。
下述实施例中涉及的脑心浸液购自青岛海博生物技术有限公司。
下述实施例中涉及的培养基如下:
拟杆菌特异性筛选培养基:43.1g布氏培养基粉末均匀溶于1L水后,加入0.01‰的氯化血红素及0.01‰的维生素K1,121℃灭菌15min。待降温至50℃时,加0.1‰的卡那霉素、0.0075‰的万古霉素及5%的绵羊血后,混匀倒入无菌的培养皿中。
BHI液体培养基:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0。
BHI固体培养基:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L、琼脂20g/L,pH为7.0。
下述实施例中涉及的普通拟杆菌菌悬液的制备方法如下:
将普通拟杆菌划线于BHI固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于BHI液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于BHI液体培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到普通拟杆菌菌体;将普通拟杆菌菌体经生理盐水洗涤后重悬于浓度为200g/L的甘油溶液(含1g/L半胱氨酸盐酸盐)中至菌浓度为1×1010CFU/mL,得到菌悬液,将菌悬液于-80℃下保存待用。
实施例1:普通拟杆菌CCFM1152的分离筛选
1、样品采集
采集天津市河东区蝶桥公寓一位50岁中年男子粪便样本,样本置于装有30%甘油的大便管中,保存于装有冰袋的保温盒中,带回实验室后迅速置于-80℃冰箱待分离筛选。
2、乳酸菌的分离纯化
(1)稀释涂布:取0.5g左右的保存于30%甘油的内容物在无菌环境下加入装有4.5mL生理盐水的10mL离心管中,得到10-1稀释液,重复上述稀释步骤,依次得到10-2、10-3、10-4、10-5、10-6稀释液;
(2)涂布培养:分别吸取100μL上述10-4、10-5、10-6三个梯度稀释液于人体肠道中分离筛选拟杆菌特异性筛选培养基上,用涂布棒涂布均匀,至37℃厌氧条件下培养48h,得到稀释涂布平板;
(3)一级纯化培养:取菌落数在30~300区间的稀释涂布平板,每个样本随机挑选10个乳白色或白色,表面光滑,边缘整齐,大小不一的单菌落在BHI固体培养基上划线,放至37℃厌氧条件下培养48h,得到单菌落;
(4)二级纯化培养:取步骤(3)划线平板上单菌落分别接种于BHI液体培养基中,至37℃厌氧条件下培养20h,得到二级纯化培养液。
3、菌种保藏与鉴定
(1)菌种保藏:
将步骤2(4)获得的二级纯化培养液混匀,分别取菌体(37℃厌氧培养16-20h)至2mL干净的菌种保藏管,平行5份,其中4份加入750μL菌液和750μL 60%甘油重悬,静止30分钟后放入-80℃冰箱;1份加入1mL菌液用于菌种鉴定,6000r/min离心3min,弃上清得菌体。
(2)菌种鉴定:
步骤3(1)用于菌种鉴定的保藏管中加入1mL无菌水吹打洗菌体后,10000r/min离心1min,弃上清得菌体,加入500μL无菌水重悬,作为菌液模板;
其中,16S rDNA PCR的体系和引物分别见表1和表2;
16S rDNA PCR的条件:第一步:94℃,5min第二步:94℃,30s第三步:55℃,30s,第四步:72℃,2min,第五步:72℃,10min,第二到四步进行30个循环。
表1细菌菌种鉴定25μL 16S rDNA PCR反应体系
表2引物名称
PCR产物经核酸电泳分析确认后,送华大基因测序;将测序返回的27F和1492R拼接序列上传到NCBI的BLAST(http://www.ncbi.nlm.nih.gov/BLAST)进行种属确认;比对结果发现编号为CCFM1152菌株为普通拟杆菌株(Bacteroides vulgatus),其16S rDNA扩增序列如SEQ ID NO.1所示。
实施例2:普通拟杆菌CCFM1152对小鼠肠道荧光素标记葡聚糖(FITC)的作用
1、普通拟杆菌CCFM1152灌胃液的制备
将实施例1步骤2获得的普通拟杆菌CCFM1152划线于BHI固体培养基中,37℃厌氧条件下培养48h,得到单菌落;挑取BHI固体培养基上的单菌落接种于BHI液体培养基中,37℃厌氧条件下富集培养18~20h进行活化,连续活化两代,得到活化培养物;将活化培养物按2%~5%(v/v)的接种量接种于BHI液体培养基中,37℃厌氧条件下富集培养18~20h得到菌液,经8000g离心10min得到菌泥,用无菌生理盐水洗涤3次后收集菌泥,将收集得到的上述菌泥用无菌30%甘油溶液重悬得到普通拟杆菌CCFM1152悬浮液,用作工作发酵剂,放置于-20%保藏。实验之前取普通拟杆菌CCFM1152悬浮液离心,用0.85%无菌生理盐水(不含半胱氨酸盐酸盐)洗涤重悬,得到普通拟杆菌CCFM1152灌胃液(1×1010CFU/mL)。参照同样的方法获得同批次筛选到的普通拟杆菌CCFM1152、FSDLZ51K1和FSDTA11B14灌胃液。空白组和造模组每天灌胃与普通拟杆菌实验组同等剂量的无菌生理盐水(不含半胱氨酸盐酸盐)。
2、实验动物
SPF级8周龄雄性BALB/C小鼠,购于上海斯莱克有限公司;饲养于25±2℃、相对湿50±5%、12h光照12h黑暗的标准化实验室中,适应性喂养一周后开始实验。
3、实验方法
取6-8周龄健康雌性C57小鼠60只,随机分为6组,每组10只,6组分别为:DSS组、正常组和普通拟杆菌CCFM1152、CCFM1152、FSDLZ51K1或FSDTA11B14干预组。
整个实验周期为10天,正常组饮用无菌水作为安慰剂,DSS组自由饮用含30g/LDSS的水并且按照100μL的剂量每天灌胃无菌生理盐水(不含半胱氨酸盐酸盐),其他四组干预组自由饮用含30g/L DSS的水,并且每天灌胃步骤1获得的灌胃液,灌胃剂量均为100μL/只C57小鼠。
从实验第一天起记录每只小鼠的体重以及血便和腹泻情况;第7天收集小鼠粪便置于2mL离心管中,置-80℃冰箱存放。
实验结束后,所有小鼠禁食不禁水24h后,将配置好的125mg/mL异硫氰酸荧光素葡聚糖(FITC-dextran)给每只小鼠灌胃(剂量:600mg/kg),1h后收集血清(2400g,15min),用血清中FITC-dextran的含量来表征肠道通透性;随后处死小鼠;取部分小鼠结肠组织置于4%多聚甲醛溶液中用于组织切片观察,剩下的结肠分段置于2mL离心管中置于-80℃冰箱。
4、小鼠体重和结肠长度变化
DSS诱导小鼠结肠炎会导致小鼠体重下降和结肠缩短,因此,体重和结肠长度是评价结肠炎小鼠炎症严重程度的重要指标。
体重变化如图1所示,与正常组比较,DSS组小鼠体重显著下降,说明溃疡性结肠炎模型构造成功;与DSS组相比,四株普通拟杆菌均显著增加了小鼠体重。其中普通拟杆菌CCFM1152和CCFM153干预组小鼠的体重降低比例分别为DSS组的51.55%和64.65%。
图2是结肠长度变化,正常组小鼠的结肠长度最长,其他组小鼠的结肠长度都有不同程度的下降;与DSS组相比,普通拟杆菌CCFM1152组和普通拟杆菌CCFM153组小鼠的结肠长度明显提高,分别提高了1.22和1.19倍。
图3是肠道通透性指标,用酶标仪检测FITC-dextran的含量(吸光度490nm),FITC-dextran含量下降说明肠道通透性降低。普通拟杆菌CCFM1152组和普通拟杆菌CCFM153组小鼠FITC-dextran含量仅是DSS组的60.87%和64.47%,与正常组相差较小,说明普通拟杆菌CCFM1152和CCFM153能有效降低肠道通透性,恢复肠道粘膜损伤。
5、小鼠结肠组织切片观察
取HE染色的结肠组织切片,在光学显微镜下观察组织形态变化。结肠组织切片观察结果如图2所示,正常组小鼠结肠粘膜上皮细胞完整,隐窝正常,腺体排列整齐有序,且无溃疡存在;与正常组相比,DSS组小鼠则出现了严重的结肠损伤和急性结肠炎症状,伴随溃疡,隐窝破坏,以及严重的炎性;给小鼠灌胃普通拟杆菌CCFM1152后可以显著改善这些状态,与正常组结肠组织形态接近。
图4是结肠组织病理评分,具体评价标准主要参考2020年发表的一篇论文(https://doi.org/10.1007/s00394-020-02200-9)。结果表明与DSS组相比,只有普通拟杆菌CCFM1152组可以显著降低DSS引起的病理评分,其余三组普通拟杆菌组小鼠的病理评分指数显著上升。
以上实验结果表明,普通拟杆菌CCFM1152能够很好地保护结肠粘膜的完整性,减少炎症对结肠的损伤。
实施例3:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备牛乳,牛乳的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到悬浮液;将悬浮液在温度37℃下预培养60min后冻干,得到菌剂;
其中,培养基的制备方法为:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/L L-谷氨酸钠;
(2)将脱脂奶在95℃热杀菌20min后冷却至4℃,得到原料;在原料中添加步骤(1)制得的菌剂至浓度为不低于1×106CFU/mL,得到牛乳(牛乳需在4℃下冷藏保存)。
实施例4:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备豆奶,豆奶的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到悬浮液;将悬浮液在温度37℃下预培养60min后冻干,得到菌剂;
其中,培养基的制备方法为:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/L L-谷氨酸钠;
(2)将大豆在温度80℃下浸泡2h后去除大豆皮,得到去皮大豆;将去皮大豆沥去浸泡水后加沸水磨浆,得到豆浆;将豆浆在高于80℃的温度条件下保温12min,得到熟豆浆;将熟豆浆用150目筛网过滤后离心分离,得到粗豆奶;将粗豆奶加热到温度140~150℃后迅速导入真空冷却室进行抽真空,使得粗豆奶中的异味物质随着水蒸汽迅速排出,得到熟豆奶;将熟豆奶降温至约37℃后在熟豆奶中添加步骤(1)制得的菌剂至浓度为不低于1×106CFU/mL,得到豆奶(豆奶需在4℃下冷藏保存)。
实施例5:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备蔬菜饮料,蔬菜饮料的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到悬浮液;将悬浮液在温度37℃下预培养60min后冻干,得到菌剂;
其中,培养基的制备方法为:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/L L-谷氨酸钠;
(2)将新鲜蔬菜洗净后榨汁,得到蔬菜汁;将蔬菜汁在温度140℃下高温热杀菌2秒,得到杀菌后的蔬菜汁;将杀菌后的蔬菜汁降温至约37℃后在杀菌后的蔬菜汁中添加步骤(1)制得的菌剂至浓度为不低于1×106CFU/mL,得到蔬菜饮料(蔬菜饮料需在4℃下冷藏保存)。
实施例6:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备胶囊制品,胶囊制品的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗2次后用脱脂乳重悬至浓度为2×1010CFU/mL,得到悬浮液;
(2)将步骤(1)制得的悬浮液添加至浓度为3%的海藻酸钠溶液中至浓度为2×109CFU/mL后,充分搅拌,使得普通拟杆菌CCFM1152的细胞均匀地分散于海藻酸钠溶液中,得到混合液;将混合液挤压到浓度为2%的氯化钙溶液中形成胶粒;待形成的胶粒静止固化30min后,过滤收集胶粒;将收集得到的胶粒进行冷冻干燥48h,得到粉剂;将粉剂装入到药用胶囊中,得到胶囊制品。
实施例7:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备发酵乳,发酵乳的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到悬浮液;将悬浮液在温度37℃下预培养60min后冻干,得到冻干粉;
其中,培养基的制备方法为:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/L L-谷氨酸钠;
(2)将冻干粉与商业干粉发酵剂保加利亚乳杆菌和商业干粉发酵剂嗜热链球菌按照质量比1:1:1的比例混合,得到发酵剂;
(3)将糖添加至鲜奶中至浓度为5%,得到混合液;将混合液在65℃、20MPa的条件下进行均质后在95℃下保温杀菌5min,得到发酵原料;将发酵原料降温至35℃后以0.03%(v/v)的接种量将步骤(2)制得的发酵剂接种至发酵原料中,于35℃下保温发酵16h,得到发酵乳;将发酵乳于42℃的条件下凝乳后,在4℃下冷藏24h进行后熟,得到发酵乳成品。
实施例8:普通拟杆菌CCFM1152的应用
普通拟杆菌CCFM1152可用于制备片剂,片剂的具体制备过程如下:
(1)将实施例1获得的普通拟杆菌CCFM1152的二级纯化培养液以3%(v/v)的接种量接种到培养基中,在温度37℃下培养18h,得到菌液;将菌液离心,得到菌泥;将菌泥用pH7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到悬浮液;将悬浮液在温度37℃下预培养60min后冻干,得到菌粉;
其中,培养基的制备方法为:脑心浸液中加入半胱氨酸盐酸盐1g/L、氯化血红素0.01g/L和维生素K1 0.002g/L,pH为7.0;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/L L-谷氨酸钠;
(2)称取步骤(1)制得的菌粉25.7重量份、淀粉55.0重量份、纤维素衍生物4.5重量份、羧甲基淀粉钠12.0重量份、滑石粉0.8重量份、蔗糖1.0重量份与水1.0重量份,得到原材料;将原材料混合,得到湿颗粒;将湿颗粒用中南制药机械厂的压片机进行压片后使用青州市益康中药机械有限公司的小型药物干燥机进行干燥,得到片剂。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
<120> 一株能够保护肠道通透性的普通拟杆菌及其应用
<130> BAA210327A
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1355
<212> DNA
<213> 人工序列
<400> 1
gttacgcact tcaggtaccc ccggctccca tggcttgacg ggcggtgtgt acaaggcccg 60
ggaacgtatt caccgcgccg tggctgatgc gcgattacta gcgaatccag cttcgtggag 120
tcgggttgca gactccagtc cgaactgaga gaggtttttg ggattggcat ccactcgcgt 180
ggtagcggcc ctctgtaccc cccattgtaa cacgtgtgta gccccggacg taagggccgt 240
gctgatttga cgtcatcccc accttcctca catcttacga tggcagtctt gtcagagtcc 300
tcagcggaac ctgttagtaa ctgacaacaa gggttgcgct cgttatggca cttaagccga 360
cacctcacgg cacgagctga cgacaaccat gcagcacctt cacagatgcc ttgcggctta 420
cggctttcac cgtaattcat ctgcaattta agcccgggta aggttcctcg cgtatcatcg 480
aattaaacca catgttcctc cgcttgtgcg ggcccccgtc aattcctttg agtttcaccg 540
ttgccggcgt actccccagg tggaatactt aacgctttcg cttggccgct tgcagtatat 600
cgcaaacagc gagtattcat cgtttaccgt gtggactacc agggtatcta atcctgtttg 660
atacccacac tttcgagcct caatgtcagt tgcagcttag caggctgcct tcgcaatcgg 720
agttcttcgt gatatctaag catttcaccg ctacaccacg aattccgcct gcctcaactg 780
cactcaagat atccagtatc aactgcaatt ttacggttga gccgcaaact ttcacaactg 840
acttaaacat ccatctacgc tccctttaaa cccaataaat ccggataacg ctcggatcct 900
ccgtattacc gcggctgctg gcacggagtt agccgatcct tattcataaa gtacatgcaa 960
acgggtatgc atacccgact ttattccttt ataaaagaag tttacaaccc atagggcagt 1020
catccttcac gctacttggc tggttcaggc ctgcgcccat tgaccaatat tcctcactgc 1080
tgcctcccgt aggagtttgg accgtgtctc agttccaatg tgggggacct tcctctcaga 1140
acccctatcc atcgaagact aggtgggccg ttaccccgcc tactatctaa tggaacgcat 1200
ccccatcgtc taccggaata cctttaatca tgtgaacatg tggactcatg atgccatctt 1260
gtattaatct tcctttcaga aggctgtcca agagtagacg gcaggttgga tacgtgttac 1320
tcacccgtgc gccggtcgcc atcggcctta gcaag 1355
Claims (1)
1.普通拟杆菌(Bacteroides vulgatus)CCFM1152在制备改善溃疡性结肠炎的药物中的应用;
所述普通拟杆菌CCFM1152已于2020年11月9日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No.61279。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110377659.9A CN113122472B (zh) | 2021-04-08 | 2021-04-08 | 一株能够保护肠道通透性的普通拟杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110377659.9A CN113122472B (zh) | 2021-04-08 | 2021-04-08 | 一株能够保护肠道通透性的普通拟杆菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113122472A CN113122472A (zh) | 2021-07-16 |
CN113122472B true CN113122472B (zh) | 2022-07-22 |
Family
ID=76775318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110377659.9A Active CN113122472B (zh) | 2021-04-08 | 2021-04-08 | 一株能够保护肠道通透性的普通拟杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113122472B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114053310B (zh) * | 2022-01-17 | 2022-08-26 | 中国疾病预防控制中心传染病预防控制所 | 普通拟杆菌益生菌cgmcc no.17140在制备降脂药物中的应用 |
CN115287235A (zh) * | 2022-08-11 | 2022-11-04 | 华中农业大学 | 提高鸡肠道免疫力的复合益生菌制剂及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143520A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内ビフィズス菌生育促進剤 |
CN102947441A (zh) * | 2010-06-01 | 2013-02-27 | 穆尔研究企业有限责任公司 | 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法 |
WO2020008149A1 (fr) * | 2018-07-04 | 2020-01-09 | Institut National De La Recherche Agronomique | Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin |
CN111269852A (zh) * | 2020-02-13 | 2020-06-12 | 中国疾病预防控制中心传染病预防控制所 | 普通拟杆菌菌株及在制备炎症性肠病治疗药物中的应用 |
-
2021
- 2021-04-08 CN CN202110377659.9A patent/CN113122472B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143520A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内ビフィズス菌生育促進剤 |
CN102947441A (zh) * | 2010-06-01 | 2013-02-27 | 穆尔研究企业有限责任公司 | 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法 |
WO2020008149A1 (fr) * | 2018-07-04 | 2020-01-09 | Institut National De La Recherche Agronomique | Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin |
CN111269852A (zh) * | 2020-02-13 | 2020-06-12 | 中国疾病预防控制中心传染病预防控制所 | 普通拟杆菌菌株及在制备炎症性肠病治疗药物中的应用 |
Non-Patent Citations (1)
Title |
---|
Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis;Naofumi Yoshida等;《Circulation》;20181127;第138卷(第2期);第2486-2498页,参见全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN113122472A (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106834187B (zh) | 一种两歧双歧杆菌及其用途 | |
CN112322528B (zh) | 一株可干预代谢综合征的鼠李糖乳杆菌及应用 | |
CN112322527A (zh) | 一株可干预代谢综合征的罗伊氏乳杆菌及应用 | |
JP6837015B2 (ja) | たとえば、細菌性膣炎の治療のためのLactobacillus rhamnosus(ラクトバチルス・ラムノサス)細菌 | |
CN113122472B (zh) | 一株能够保护肠道通透性的普通拟杆菌及其应用 | |
CN113403231B (zh) | 一株可干预代谢综合征的罗伊氏乳杆菌ccfm1178及应用 | |
CN113943681B (zh) | 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌 | |
CN114854638B (zh) | 一株高效表达腺苷脱氨酶mRNA缓解结肠炎副干酪乳杆菌 | |
CN111560325B (zh) | 一株能够调节肠道紧密连接蛋白的发酵乳杆菌及其应用 | |
CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
CN112625968B (zh) | 一株缓解内毒素感染的粘膜乳杆菌及应用 | |
CN117143765A (zh) | 一株调控肠道稳态缓解顽固性便秘的长双歧杆菌长亚种及其应用 | |
CN114933992B (zh) | 一种长双歧杆菌及其复合制剂在缓解溃疡性结肠炎中的应用 | |
CN115992059A (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
CN111869879B (zh) | 一种能够调节cyp1a1基因表达的产品 | |
CN109757730B (zh) | 一种具有降血脂、血压以及血糖的组合物及其制备方法 | |
CN114410532A (zh) | 一株降低血浆氧化三甲胺和盲肠三甲胺水平的长双歧杆菌及其应用 | |
CN113122471A (zh) | 一株高利用低聚半乳糖的假小链双歧杆菌及其应用 | |
CN113699061B (zh) | 一株可缓解溃疡性结肠炎的菌株Phocaeicola sp.及其应用 | |
CN113234619B (zh) | 一株两歧双歧杆菌及其在缓解肠道损伤中的应用 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
CN113186124B (zh) | 一株能够缓解由脂多糖引起的急性肠道损伤的普通拟杆菌 | |
CN114561325B (zh) | 一株能够改变模拟胃肠道环境中胆汁酸含量且具有缓解便秘作用的长双歧杆菌及其应用 | |
CN114874954B (zh) | 一种能够促进肠道中短链脂肪酸产生的弯曲乳杆菌及其应用 | |
CN113186123B (zh) | 一株能够调控肠道阿克曼菌属相对丰度的普通拟杆菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |